<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
"http://www.w3.org/TR/html4/strict.dtd">
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

	<!-- Basic Page Needs
  ================================================== -->
    <script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/jquery-1.8.3.min.js" type="text/javascript"></script>
    <script type="text/x-mathjax-config">
	MathJax.Hub.Config({
	  "HTML-CSS": { linebreaks: { automatic: true } },
	         SVG: { linebreaks: { automatic: true } }
	});
	</script>
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
	<meta charset="utf-8">
	<title>Heart &amp; Circulation</title>
	<meta name="description" content="Course Notes for Heart &amp; Circulation">
	<meta name="author" content="Kevan Lu">
	<meta name="robots" content="noindex,nofollow"/>
	
	<!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0"/>
	
	<!-- CSS
  ================================================== -->
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/layout.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/content.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/print.css">
	<link href="http://maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css" rel="stylesheet">	
	
	<script>
	  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	  })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

	  ga('create', 'UA-40381402-3', 'auto');
	  ga('send', 'pageview');
	</script>

	<!-- Favicons
	================================================== -->
	<link rel="shortcut icon" href="https://dl.dropboxusercontent.com/u/157117/Class%20References/favicon.png" type="image/png">

	<!-- iOS Icons
	================================================== -->
	<link href="https://dl.dropboxusercontent.com/u/157117/notes/resources/images/icon-iphone-retina.png" rel="apple-touch-icon"/>
</head>
<body>
    <div id="home-overlay">
	<div class="index"><a href="http://www.schulichnotes.com"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<div id="header-search-icon"><a id="header-search-button"><i class="fa fa-search"></i></a></div>
</div>
<div id="header-search-bar">
	<form class="search" action="http://www.schulichnotes.com/cardiology/search.html">
	<div><input type="text" value="Search Heart &amp; Circulation" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	</form>
</div>
<div id="overlay"><h1><a style="border:none;" href="http://www.schulichnotes.com/cardiology">Heart &amp; Circulation</a></h1></div>
    <div class="sidebar-background"></div>
    <div class="sidebar">
        <!-- Displays a Search Bar-->
<div class="search-wrapper">
	<div class="index"><a href="http://www.schulichnotes.com"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<form class="search" action="http://www.schulichnotes.com/cardiology/search.html">
	<div style="float: left;"><input type="text" value="Search Heart &amp; Circulation" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	<div style="float: left;"><input type="button" id="tipue_search_button" onclick="this.form.submit();"></div>
	<div style="clear: left;"></div>
	</form>
</div>

<div class="course-index">
	<a href="http://www.schulichnotes.com/cardiology">Heart &amp; Circulation</a>
</div>

        <nav>	
	<li class="week">Week 1</li>
	<ul>
		<li class="day">January 13</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/13/intro-cardiac-physiology.html">Introduction to Cardiac Physiology</a></li></ul>
		<li class="day">January 14</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/14/intro-cardiac-physiology-2.html">Introduction to Cardiac Physiology II</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/14/heart-pump.html">The Heart as a Pump I</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/14/bp-reg-vascular-flow.html">BP Regulation &amp Vascular Flow</a></li></ul>
		<li class="day">January 15</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/15/cardiac-electrical-physiology.html">Cardiac Electrical Physiology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/15/interpreting-ecgs-1a.html">Interpreting ECGs Ia</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/15/interpreting-ecgs-1b.html">Interpreting ECGs Ib</a></li></ul>
		<li class="day">January 16</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/16/heart-pump-2.html">The Heart as a Pump II</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/16/heart-pump-3.html">The Heart as a Pump III</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/16/anatomy-lab-heart.html">Heart Anatomy Lab</a></li></ul>
		<li class="day">January 17</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/17/intro-cardiovascular-pharmacology.html">Cardiovascular Pharmacology I</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/17/intro-cardiovascular-pharmacology-2.html">Cardiovascular Pharmacology II</a></li></ul>
	</ul>
	<li class="week">Week 2</li>
	<ul>
		<li class="day">January 20</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/20/valvular-heart-disease-cases.html">Valvular Heart Disease Cases</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/20/imaging-cardiovascular-disease.html">Imaging in Cardiovascular Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/20/into-heart-sounds.html">Introduction to Heart Sounds</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/20/clinical-assessment-heart-sounds.html">Clinical Assessment of Heart Sounds</a></li></ul>
		<li class="day">January 21</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/21/aortic-stenosis.html">Aortic Stenosis</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/21/mitral-regurgitation.html">Mitral Regurgitation</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/21/mitral-stenosis.html">Mitral Stenosis</a></li></ul>
		<li class="day">January 22</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/22/aortic-regurgitation.html">Aortic Regurgitation</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/22/endocarditis.html">Endocarditis</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/22/interpreting-ecgs-2.html">Interpreting ECGs II</a></li></ul>
		<li class="day">January 23</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/23/outline-congenital-heart-disease.html">An Outline of Congenital Heart Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/23/exercise-physiology.html">Exercise Physiology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/23/valvular-pericardial-cases.html">Valvular Pericardial Cases</a></li></ul>
		<li class="day">January 24</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/24/surgical-management-valvular-disease.html">Surgical Management in Valvular Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/24/case-based-learning.html">Case Based Learning</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/24/clinical-problems-pediatric-cardiology.html">Clinical Problems in Pediatric Cardiology</a></li></ul>
	</ul>
	<li class="week">Week 3</li>
	<ul>
		<li class="day">January 27</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/27/case-based-learning-atherosclerosis.html">Atherosclerosis Case Based Learning</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/27/investigations-ischemic-heart-disease.html">Investigations in Ischemic Heart Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/27/vascular-pathology.html">Vascular Pathology</a></li></ul>
		<li class="day">January 28</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/28/cholinergic-pharmacology-1.html">Cholinergic Pharmacology I</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/28/physiology-hypertension.html">Physiology of Hypertension</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/28/microcirculation-physiology.html">Microcirculation Physiology</a></li></ul>
		<li class="day">January 29</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/29/pharmacology-dyslipidemia.html">Pharmacology for Dyslipidemia</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/29/lipids-genes-CAD.html">Lipids, Genes, and CAD</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/29/anatomy-lab-mediastinum.html">Mediastinum Anatomy Lab</a></li></ul>
		<li class="day">January 30</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/30/aneurysms.html">Aneurysms</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/30/case-based-learning-peripheral-vascular-disease.html">Peripheral Vascular Disease Cases</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/30/management-hypertension.html">Management of Hypertension</a></li></ul>
		<li class="day">January 31</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/31/vascular-small-group.html">Vascular Small Group Session</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/31/hypertension-small-group.html">Hypertension Small Group Session</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/01/31/cholinergic-pharmacology-2.html">Cholinergic Pharmacology II</a></li></ul>
	</ul>
	<li class="week">Week 4</li>
	<ul>
		<li class="day">Monday, February 3</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/03/primary-prevention-cardiovascular-disease.html">Primary Prevention of Cardiovascular Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/03/secondary-prevention-cardiovascular-disease.html">Secondary Prevention of Cardiovascular Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/03/management-chronic-coronary-disease.html">Management of Chronic Coronary Disease</a></li></ul>
		<li class="day">Tuesday, February 4</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/04/coronary-circulation.html">Coronary Circulation</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/04/coronary-artery-disease-mi-pci-1.html">Coronary Artery Disease &mdash; MI &amp; PCI I</a></li></ul>
		<li class="day">Wednesday, February 5</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/05/nutrition-cardiovascular-disease.html">Nutrition and Cardiovascular Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/05/ischemic-heart-disease-pathology.html">Ischemic Heart Disease Pathology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/05/coronary-artery-disease-mi-pci-2.html">Coronary Artery Disease &mdash; MI &amp; PCI II</a></li></ul>
		<li class="day">Thursday, February 6</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/06/pediatric-cardiology.html">Child Health &mdash; Pediatric Cardiology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/06/chest-pain-small-group.html">Chest Pain Small Group</a></li></ul>
		<li class="day">Friday, February 7</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/07/surgical-management-cardiovascular-disease.html">Surgical Management of Cardiovascular Disease</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/07/intervention-cardiac-patient-cases.html">Intervention in Cardiac Patient Cases</a></li></ul>
	</ul>
	<li class="week">Week 5</li>
	<ul>
		<li class="day">Monday, February 10</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/10/heart-failure-cases.html">Heart Failure Cases</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/10/heart-failure-1.html">Heart Failure I</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/10/physiology-heart-failure.html">Physiology of Heart Failure</a></li></ul>
		<li class="day">Tuesday, February 11</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/11/heart-failure-2.html">Heart Failure II</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/11/heart-failure-3.html">Heart Failure III</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/11/heart-failure-small-groups.html">Heart Failure Small Groups</a></li></ul>
		<li class="day">Wednesday, February 12</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/12/mechanism-arrythmia.html">Mechanism of Arrythmia</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/12/antiarrythmics.html">Antiarrythmics</a></li></ul>
		<li class="day">Thursday, February 13</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/13/atrial-fibrillation.html">Atrial Fibrillation</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/13/supraventricular-tachycardia.html">Supraventricular Tachycardia</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/13/ventricular-tachycardia.html">Ventricular Tachycardia</a></li></ul>
		<li class="day">Friday, February 14</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/14/interpreting-ecgs-3.html">Interpreting ECGs III &mdash; Cases</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/14/bradycardia.html">Bradycardia</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/14/syncope.html">Syncope</a></li></ul>
	</ul>
	<li class="week">Week 6</li>
	<ul>
		<li class="day">Tuesday, February 18</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/18/end-of-life-care.html">End of Life Care</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/18/arrythmia-small-groups.html">Arrythmia Small Groups</a></li></ul>
		<li class="day">Wednesday, February 19</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/19/ecg-exercises.html">ECG Exercises</a></li><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/19/integrated-wrap-up-cases.html">Integrated Wrap-up Cases</a></li></ul>
		<li class="day">Thursday, February 20</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/cardiology/2014/02/20/exam-review-cardiovascular-jeopardy.html">Final Exam Review</a></li></ul>
	</ul>
</nav>
    </div>
    <div class="content-offset">
        <div class="content-background"></div>
        <div class="content">
            <div class="single post">
                <!-- Post Layout -->
                <div class="title"><h1>Antiarrythmics</h1></div>
                <info datetime="2014-02-12">
                    <span class="author"><a href="https://dl.dropboxusercontent.com/u/157117/notes-reference/jekyll/_site/contributors.html#kevanlu">Kevan Lu</a></span>
                    <span class="date">Wednesday, February 12, 2014</span>
                </info>
                <div class="body"><h2 id='review_of_the_mechanisms_of_arrhythmia'><strong>Review of the Mechanisms of Arrhythmia</strong></h2>

<ul>
<li>Cardiomyocytes are capable of <em>endogenously triggering depolarization</em>.</li>

<li>Upslope of depolarization reaches a critical threshold. This triggers a <em>movement of calcium</em> (versus the sodium output that is seen typically), which causes repolarization.</li>

<li>Arrythmias can occur because of <em>abnormal automaticity</em>, where this endogenous depolarization is dystfunctional, or <em>reentry</em>, where there is an alternative circuit through the heart that causes <em>looping</em>.</li>
</ul>

<h4 id='how_antiarrythmics_can_affect_automaticity'><strong>How Antiarrythmics can affect automaticity</strong></h4>

<ol>
<li><strong>Decrease the slope of Phase 4 depolarization</strong> &#8594; eg. <em>Beta blockers</em></li>

<li><strong>Increase threshold</strong> &#8594; eg. <em>Ca<sup>2+</sup> channel blockers.</em></li>

<li><strong>Prolong Action Potential</strong> &#8594; <em>eg K<sup>+</sup> channel blockers.</em></li>

<li><strong>Diastolic Potental</strong> &#8594; eg. <em>Acetylcholine (vagal)</em></li>
</ol>

<h2 id='principles_of_treating_arrhythmias'><strong>Principles of Treating Arrhythmias</strong></h2>

<ol>
<li>
<p><strong>Identify and treat precipitating factors.</strong></p>

<ul>
<li>For instance, ischemic tissue.</li>

<li>Activation of the sympathetic nervous system &#8594; shock, strenuous exercise.</li>

<li>Electrolyte abnormalities</li>

<li>Drugs that may be pro-arrythmic.</li>
</ul>
</li>

<li>
<p><strong>Decide on your goal.</strong></p>

<ul>
<li>
<p><strong>Not all arrythmias need treating:</strong></p>

<ul>
<li><em>Sinus tachycardia</em> &#8594; you don&#8217;t need to treat the condition itself, because it&#8217;s almost always a sign of an <em>underlying condition</em>. If anything, this is usually a physiological response to an acute condition!</li>

<li><em>Sinus bradycardia</em> &#8594; This can be seen in athletes where exercise has increased parasympathetic tone!</li>

<li><em>Atrial fibrillation with a controlled rate.</em></li>
</ul>
</li>

<li>
<p><strong>Non-pharmacological therapy (electricity):</strong></p>

<ul>
<li>
<p>A pacemaker in patients with a pathological bradycardia.</p>
</li>

<li>
<p>Defibrillators for patients with severe arrhythmias.</p>
</li>

<li>
<p>A general rule of thumb is:</p>

<ul>
<li>If the patient is <em>stable</em> &#8594; antiarrythmics are okay.</li>

<li>If the patient is <em>unstable</em> &#8594; electrical interventions like defibrillators should be used.</li>

<li>If the patient is <em>dead</em> &#8594; CPR, electricity, drugs, use everything!</li>
</ul>
</li>
</ul>
</li>

<li>
<p>Rate or rhythm control can be done in atrial fibrillation.</p>

<ul>
<li>In the case of atrial fibrillation, <em>anticoagulation</em> would also be considered because it would increase the risk of having static flow in the atria due to impaired atrial systole.</li>
</ul>
</li>
</ul>
</li>

<li>
<p><strong>Minimize Risks</strong></p>

<ul>
<li>
<p>Look for <em>drug-drug interations</em>.</p>
</li>

<li>
<p>Try to choose dose to maximize effect and minimize side-effects. Many drugs have renal excretion, and a narrow therapeutic window.</p>
</li>

<li>
<p>Some anti-arrythmics can actually have a pro-arrythmic effect:</p>

<ul>
<li>Drugs that <em>prolong the QT-interval</em> have a risk of causing torsades.</li>

<li>Drugs that <em>slow the heart rate</em> have a risk of causing bradyarrythmias.</li>

<li><em>Digoxin</em> can cause arrythmias in toxic doses. You have to carefully titrate the dosage!</li>
</ul>
</li>
</ul>
</li>
</ol>

<h2 id='classification_of_antiarrhythmic_drugs'><strong>Classification of Antiarrhythmic Drugs</strong></h2>

<ul>
<li>
<p>There are 4 classes of antiarrhythmic drugs, following what is known as the <em>Singh Vaughan Williams Classification</em>:</p>

<ol>
<li><strong>Class I: Na<sup>+</sup> channel blockers</strong></li>

<li><strong>Class II: Beta blockers</strong></li>

<li><strong>Class III: K<sup>+</sup> channel blockers</strong></li>

<li><strong>Class IV: Ca<sup>2+</sup> channel blockers</strong></li>
</ol>
</li>
</ul>

<blockquote>
<h4 id='singh_vaughan_williams_classification'><strong>Singh Vaughan Williams Classification</strong></h4>

<ol>
<li><strong>Class I: Na<sup>+</sup> channel blockers</strong></li>

<li><strong>Class II: Beta blockers</strong></li>

<li><strong>Class III: K<sup>+</sup> channel blockers</strong></li>

<li><strong>Class IV: Ca<sup>2+</sup> channel blockers</strong></li>
</ol>
</blockquote>

<h3 id='1_class_i_sodium_channel_blockers'>1. <strong>Class I Sodium Channel Blockers</strong></h3>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/0ql_fbou.png' />
<ul>
<li>block Na<sup>+</sup> channels.</li>

<li>affect <em>phase 0</em> (rapid depolarization) in cardiac cells (non-nodal)</li>

<li>decrease slope of <em>phase 0</em>, which prolongs the action potential and decreases the conduction velocity</li>

<li>may be useful for reentrant arrhythmias, by changing the rate of conduction through a limb in the circuit.</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><em>Na<sup>+</sup> channel blockers</em> slow the speed of <em>phase 0</em>, which <em>prolongs action potentials</em>.</li>
</ul>
</blockquote>

<h3 id='2_class_ii_beta_blockers'>2. <strong>Class II Beta Blockers</strong></h3>

<ul>
<li>
<p>These block <em>&#946;-adrenergic receptors</em>, as described previously.</p>
</li>

<li>
<p>These act to slow the heart rate by:</p>

<ul>
<li>Increasing AV node conduction time.</li>

<li>Prolonging AV node refractoriness.</li>

<li>Modulating adrenergic tone.</li>
</ul>
</li>

<li>
<p>Basically, they <strong>destimulate the AV node</strong>.</p>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><em>Beta blockers</em> function to <em>destimulate the AV node</em> &#8594; they <em>slow AV conduction</em>, and <em>increase AV node refractoriness</em>.</li>
</ul>
</blockquote>

<h3 id='3_class_iii_potassium_channel_blockers'>3. <strong>Class III Potassium Channel Blockers</strong></h3>

<ul>
<li>
<p>This slows the <em>rate of repolarization</em>, which was effected by potassium influx.</p>
</li>

<li>
<p>Because they act to prolong action potentials by prolonging depolarization, they <em>increase the QT interval</em>.</p>

<ul>
<li>Hence potassium channel blockers should be closely monitored because they can <strong>cause Torsades</strong>!</li>
</ul>
</li>

<li>
<p>This prolonged depolarization does however act to prolong the refractory period, so they are also useful for re-entry arrythmias, where the difference in refractoriness is key in causing re-entry.</p>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><em>K<sup>+</sup> channel blockers</em> function to <em>slow the rate of depolarization</em>. This <em>prolongs the QT</em>, which has a risk for <strong>torsades</strong>.</li>
</ul>
</blockquote>

<h3 id='4_class_iv_calcium_channel_blockers'>4. <strong>Class IV Calcium Channel Blockers</strong></h3>

<ul>
<li>
<p>As mentioned in our lecture on <a href='http://www.schulichnotes.com/cardiology/2014/01/17/intro-cardiovascular-pharmacology-2.html'>Cardiovascular Pharmacology</a>, there are <em>two types of calcium channel blockers</em>:</p>

<ol>
<li><strong>Dihydropyridines</strong> &#8594; <em>vascular selective</em>, vasodilation.</li>

<li><strong>Nondihydropyridines</strong> &#8594; <em>cardiac selective</em>, affect the SA and AV nodes.</li>
</ol>
</li>

<li>
<p>In the case of <em>arrythmias</em>, we&#8217;d obviously use the <strong>nondihydropyridines</strong> only. These would include <em>Verapamil</em> and <em>Diltiazem</em>.</p>

<ul>
<li>You wouldn&#8217;t use the dihydropyridines (the &#8216;__pine&#8217; drugs), in these cases!</li>
</ul>
</li>

<li>
<p>They affect the sinus and AV node, by increasing the threshold to depolarization.</p>

<ul>
<li>Recall that <em>phase 0 depolarization</em> depends on a <em>spontaneous influx of calcium ions</em>.</li>

<li>If calcium channels are blocked, then it&#8217;s harder to have this spontaneous depolarization!</li>
</ul>
</li>

<li>
<p>So Non-<abbr title='Dihydropyridine'>DHP</abbr> <abbr title='Calcium Channel Blocker'>CCB</abbr>s have the following functions:</p>

<ol>
<li><em>Decreases AV node conduction velocity</em></li>

<li><em>Decreases heart rate</em> via the sinus node effect.</li>
</ol>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><strong>Nondihydropyridine</strong> Calcium channel blockers such as <em>Verapamil</em> and <em>Diltiazem</em>, affect depolarization of nodal tissues, <em>reducing AV node velocity</em> and <em>decreasing heart rate</em>.</li>
</ul>
</blockquote>

<h4 id='limitations_of_singh_vaughan_williams_classification'><strong>Limitations of Singh Vaughan Williams Classification</strong></h4>

<ol>
<li>
<p>Drugs in the same class can act in <em>several different ways</em></p>

<ul>
<li>For example, <em>amiodarone</em>, and <em>sotalol</em>.</li>

<li>Sotalol is a beta-blocker (hence the &#8216;lol&#8217; suffix), but it&#8217;s also a potassium channel blocker. So technically it&#8217;s both in Class II and Class III.</li>
</ul>
</li>

<li>
<p>Classification does not account for metabolites.</p>

<ul>
<li>For instance, the metabolite could work in a different way than the drug itself.</li>
</ul>
</li>

<li>
<p>It does not include <em>digoxin</em> and <em>adenosine</em>.</p>
</li>
</ol>

<h1 id='class_i_antiarrythmics'>Class I Antiarrythmics</h1>
<hr />
<ul>
<li>
<p>Class I Antiarrythmics are split into:</p>

<ul>
<li><em>Class Ia</em> &#8594; <em>lengthens the action potential</em>.</li>

<li><em>Class Ib</em> &#8594; <em>shortens the action potential</em>.</li>

<li><em>Class Ic</em> &#8594; <em>has no effect on the action potential</em>.</li>
</ul>
</li>
</ul>

<h4 id='class_ia_antiarrythmics'><strong>Class Ia Antiarrythmics</strong></h4>

<ul>
<li>
<p>One example is <strong>Procainamide</strong> (Pronestyl).</p>
</li>

<li>
<p>Na<sup>+</sup> channel blocker, so it prolongs the <abbr title='Action Potential'>AP</abbr>, and slows conduction.</p>
</li>

<li>
<p>However, it has <em>anticholinergic side effects</em> &#8594; recall <strong>SLUDGE</strong>.</p>

<ul>
<li>So it&#8217;s not really used in <em>chronic cases</em>. Typically used in <em>acute cases</em>.</li>
</ul>
</li>

<li>
<p>Generally used for <em>supraventricular and ventricular arrythmias</em>.</p>
</li>

<li>
<p>Has a risk of <em>proarrythmic effects</em>.</p>
</li>
</ul>

<h4 id='class_ib_antiarrythmics'><strong>Class Ib Antiarrythmics</strong></h4>

<ul>
<li>
<p>One example is <strong>Lidocaine</strong>.</p>

<ul>
<li>Lidocaine is an older drug that blocks subtypes of sodium channels <em>specific to the ventricle</em> (and is also used as a local anesthetic).</li>

<li>Hence it&#8217;s used <strong>only in ventricular arrythmias</strong>.</li>
</ul>
</li>

<li>
<p>It seems to be particularly selective for <em>ischemic tissue</em>.</p>
</li>

<li>
<p><em><i>Not used prophylactically with MI</i></em>, because it can be toxic.</p>
</li>

<li>
<p>Lidocaine has a <em>hugely variable half life</em> &#8594; patients with CHF with poor perfusion will have a long half life!</p>

<ul>
<li>We only use it <em>intravenously</em> &#8594; it has no function orally, because it&#8217;ll be <em>metabolized by the liver</em> (recall that it&#8217;ll go from the gut &#8594; portal vein &#8594; liver &#8594; systemic circulation).</li>
</ul>
</li>

<li>
<p><strong>Lidocaine toxicity</strong></p>

<ul>
<li>CNS problems &#8594; seizures.</li>

<li>Cardiovascular collapse.</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='class_i_antiarrythmics'><strong>Class I Antiarrythmics</strong></h4>

<ul>
<li><em>Class Ia</em> = <strong>procainamide</strong>.</li>

<li><em>Class Ib</em> = <strong>lidocaine</strong>.</li>
</ul>
</blockquote>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><strong>Lidocaine</strong> (Class Ib) is <em>selective for the ventricle</em>, so it&#8217;s only used for <strong>ventricular arrythmias</strong> (especially with ischemia).</li>
</ul>
</blockquote>
<hr style='border:none; height:15px;' />
<h1 id='class_ii_antiarrythmics'>Class II Antiarrythmics</h1>
<hr />
<ul>
<li>These are the beta-blockers, as described before.</li>

<li>The &#8216;___lol&#8217; drugs would all fit here &#8594; propanolol, metoprolol, labetolol, carvedilol, etc.</li>

<li>By blocking sympathetic innervation, we reduce the conduction rate through the AV node.</li>

<li>This makes beta-blockers useful for rate control in atrial fibrillation, re-entry arrythmias, etc.</li>
</ul>

<h1 id='class_iii_antiarrythmics'>Class III Antiarrythmics</h1>
<hr />
<h3 id='1_amiodarone'>1. <strong>Amiodarone</strong></h3>

<ul>
<li>
<p><strong>Amiodarone</strong> is theoretically a <strong>Class III Antiarrythmic</strong>.</p>
</li>

<li>
<p>But in fact, <em>Amiodarone</em> has a bit of everything! Has a <em>Class I-IV behaviour</em>!</p>

<ul>
<li>This actually reduces the risk of a long-QT caused by the potassium channel blocking &#8594; it seems as if the other behaviour moderates the risk.</li>

<li>So amiodarone will have <em>less of a proarrythmic effect than other Class III medications.</em></li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><strong>Amiodarone</strong> is typically classified as a <strong>Class III</strong> antiarrythmic, but it actually has behaviour from <em>all 4 classes</em>!</li>
</ul>
</blockquote>

<ul>
<li>
<p>Clinically, amiodarone is used for <em>atrial fibrillation</em>, and <em>ventricular arrythmias</em> (much like every other antiarrythmic)!</p>
</li>

<li>
<p>Amiodarone is the drug of choice in patients with cardiac arrest due to <em>ventricular fibrillation</em> that are <em>refractory to electical shock therapy</em>.</p>
</li>

<li>
<p>Amiodarone has a <em>huge half life</em> (months) and tends to <strong>accumulate in tissues</strong>. - So when you treat a patient with it, to get them to therapeutic levels quickly, you start with a high loading dose over a couple of weeks, and then follow up with a maintenance dose.</p>
</li>

<li>
<p>Chronically, <em>amiodarone</em> is famous for a rare side effect of causing <strong>pulmonary fibrosis</strong> &#8594; scarring of the lungs.</p>

<ul>
<li><strong>Bleomycin</strong>, <strong>Amiodarone</strong>, and <strong>Nitrofurantoin</strong> are the big examples of drugs that can cause IPF.</li>

<li>See the lecture on <a href='http://www.schulichnotes.com/respirology/2014/03/05/clinical-aspects-pathology-interstitial-lung-diseases.html'>Diffuse Interstitial Lung Diseases</a>.</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><em>Chronic</em> use of amiodarone can sometimes cause <strong>pulmonary fibrosis</strong>.</li>
</ul>
</blockquote>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/q8480v0h.png' />
<ul>
<li>
<p>Since amiodarone also has an <em>iodine moiety</em> in it, it can also cause effects on the <strong>thyroid</strong>:</p>

<ul>
<li><em>Hyperthyroidism</em>.</li>

<li><em>Hypothyroidism</em>.</li>
</ul>
</li>

<li>
<p>Either can actually happen &#8594; it&#8217;s not that predictable. So we actually have to monitor the patients thyroid function (TSH, etc), and adjust accordingly.</p>
</li>
</ul>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/f02n61w0.png' />
<ul>
<li>
<p>Amiodarone can also cause <strong>pigmentation</strong> of the skin &#8594; obviously not a great side-effect.</p>

<ul>
<li>You&#8217;ll look purplish and &#8216;smurfy&#8217;.</li>
</ul>
</li>

<li>
<p>Since amiodarone has such broad effects, it also has a wide range of <em>adverse drug interactions</em>.</p>
</li>
</ul>

<blockquote>
<h4 id='adverse_effects_of_amiodarone'><strong>Adverse Effects of Amiodarone</strong></h4>

<ul>
<li>Chronic use has a small risk of causing <em>IPF</em>.</li>

<li><em>Pigmentation</em> of the skin.</li>

<li>Effects on the <em>thyroid</em> due to the presence of an iodine moiety.</li>
</ul>
</blockquote>

<h3 id='2_dronedarone'>2. <strong>Dronedarone</strong></h3>

<ul>
<li>
<p>There&#8217;s a new drug called <strong>Dronedarone</strong> which has recently hit the market that is <em>similar to amiodarone</em>, but <em>doesn&#8217;t have the iodine moiety</em>. It also has a much shorter half life.</p>

<ul>
<li>Theoretically, this means that it shouldn&#8217;t have the thyroid toxicity.</li>

<li>It also seems to show less tissue accumulation, since it&#8217;s less lipophilic.</li>

<li>Since it&#8217;s only recently been made available, we&#8217;re not yet certain what its role is.</li>
</ul>
</li>
</ul>

<h3 id='3_sotalol'>3. <strong>Sotalol</strong></h3>

<ul>
<li>
<p>Technically both <em>Class II</em> and <em>Class III</em> &#8594; it&#8217;s also a non-selective beta-blocker.</p>
</li>

<li>
<p>It blocks <em>inward potassium channels</em>, prolonging the QT, and suppressing phase 4 depolarization.</p>
</li>

<li>
<p>Clinically it&#8217;s used with ventricular arrythmias or atrial fibrillation, but not too often, because it has the risk of <strong>torsades</strong>.</p>

<ul>
<li>Recall that most Class III antiarrythmics have this risk of Torsades because they prolong the QT interval.</li>
</ul>
</li>
</ul>

<h3 id='4_new_class_iii_antiarrythmics'>4. <strong>New Class III Antiarrythmics</strong></h3>

<ul>
<li><strong>Dofetilide</strong>.</li>

<li><strong>Ibutilide</strong>.</li>

<li>There are IV drugs with a <em>rapid onset of action</em>, that are used to terminate atrial fibrillation (<em>chemical cardioversion</em>).</li>

<li>They have a significant risk of Torsades because they prolong the QT, so they&#8217;re only really used by Cardiology.</li>
</ul>

<h1 id='class_iv_antiarrythmics'>Class IV Antiarrythmics</h1>
<hr />
<ul>
<li>
<p>These are the <strong>nondihydropyridine</strong> calcium channel blockers.</p>
</li>

<li>
<p>As mentioned, they include:</p>

<ol>
<li><strong>Verapamil</strong>,</li>

<li><strong>Diltiazem</strong>.</li>
</ol>
</li>

<li>
<p>Since they have an effect on AV node conduction (along with SA node conduction), they&#8217;re very useful for <strong>re-entry arrythmias</strong> and <strong>rate control for A-fib</strong>.</p>
</li>
</ul>

<blockquote>
<h4 id='class_iv_antiarrythmics'><strong>Class IV Antiarrythmics</strong></h4>

<ul>
<li><em>Re-entry arrythmias</em> (Non-<abbr title='Dihydropyridine'>DHP</abbr> <abbr title='Calcium Channel Blocker'>CCB</abbr>s slow AV node conduction).</li>

<li><em>Rate Control with Atrial Fibrillation</em> (Non-<abbr title='Dihydropyridine'>DHP</abbr> <abbr title='Calcium Channel Blocker'>CCB</abbr>s reduce SA node automaticity).</li>
</ul>
</blockquote>

<h1 id='adenosine'>Adenosine</h1>
<hr /><span class='sidenote'>Recall that <b>adenosine</b> is a <b>nucleoside</b> &rarr; it consists of a nucleic acid plus a 5-carbon sugar. A <b>nucleotide</b> is a nucleoside with 1-3 phosphate groups as well.</span>
<ul>
<li>
<p>Used to <strong>block conduction through the AV node completely</strong>.</p>

<ul>
<li>As a result, it can often cause <em>asystole</em> &#8594; not a good thing!</li>

<li>But the half life is <em>very short</em>, at around 10 seconds, so you just have to wait (and pray), and they should recover.</li>
</ul>
</li>

<li>
<p>Used as an <em>IV bolus</em>.</p>
</li>

<li>
<p>Clinically, it&#8217;s used for:</p>

<ul>
<li>
<p><em>Re-entry supraventricular tachycardias</em>.</p>
</li>

<li>
<p><em>Diagnosing wide complex tachycardia</em>.</p>

<ul>
<li>If adenosine stops it, the ectopic pacing must be <em>supraventricular</em>.</li>

<li>If adenosine doesn&#8217;t stop it, then the ectopic pacing must occur <em>below the AV node</em>.</li>
</ul>
</li>
</ul>
</li>
</ul>

<h1 id='digoxin'>Digoxin</h1>
<hr />
<ul>
<li>
<p>As mentioned in <a href='https://dl.dropboxusercontent.com/u/157117/notes/cardiology/jekyll/_site//2014/01/17/intro-cardiovascular-pharmacology.html'>Cardiovascular Pharmacology I</a>, Digoxin has two functions:</p>

<ol>
<li><strong>Inhibit the Na<sup>+</sup>/K<sup>+</sup> ATPase</strong>.</li>

<li><strong>Indirect PSNS (vagal) effects.</strong></li>
</ol>
</li>

<li>
<p>As an antiarrythmic, we use its <em>indirect vagal effect</em>.</p>

<ul>
<li>It slows the conduction through the AV node.</li>

<li>This slows the rate in <strong>atrial fibrillation</strong>.</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<p>Digoxin has <em>two functions</em>:</p>

<ol>
<li><strong>Inhibit the Na<sup>+</sup>/K<sup>+</sup> ATPase</strong> &#8594; used to increase <em>myocardial contractility</em>.</li>

<li><strong>Indirect PSNS (Vagal) effects</strong> &#8594; used to treat <em>atrial fibrillation</em>.</li>
</ol>

<p>So the <em>only antiarrythmic role</em> for digoxin is to <em>slow the rate</em> in <em>atrial fibrillation</em>.</p>
</blockquote>

<ul>
<li>
<p>Digoxin isn&#8217;t even a very useful antiarrythmic &#8594; this vagal effect is easily overcome in patients with <em>high sympathetic tone</em> (ie, if they&#8217;re nervous, exercising, etc).</p>

<ul>
<li>Used more for patients with atrial fibrillation that are more sedentary.</li>
</ul>
</li>

<li>
<p>It also has a <em>narrow therapeutic range</em>, so there&#8217;s a risk for digitalis toxicity, which can have proarrythmic effects.</p>
</li>
</ul>

<h1 id='summary'>Summary</h1>
<hr />
<blockquote>
<h3 id='general_rules_of_thumb'><strong>General Rules of Thumb</strong></h3>

<ol>
<li>
<p><strong>Don&#8217;t combine agents in the same class</strong></p>

<ul>
<li>If you&#8217;re using <em>metoprolol</em> for a patient with CHF, then you wouldn&#8217;t give them <em>sotalol</em> for their arrythmia as well.</li>
</ul>
</li>

<li>
<p><strong>Don&#8217;t combine agents with the same side effects</strong></p>

<ul>
<li>For instance, multiple drugs that cause bradycardia, or a long QT, can exacerbate the effects &#8594; could be dangerous!</li>

<li>For instance a beta-blocker with a Non-<abbr title='Dihydropyridine'>DHP</abbr> <abbr title='Calcium Channel Blocker'>CCB</abbr> (both slow conduction through the AV node).</li>
</ul>
</li>
</ol>
</blockquote>

<blockquote>
<h3 id='question_1'><strong>Question 1</strong></h3>

<p>Which of the following would be useful in controlling ventricular rate in atrial fibrillation?</p>

<ol>
<li>Lidocaine &#8594; ventricular fibrillation only! Class Ib specific for ventricular tissue.</li>

<li><em>Verapamil</em> &#8594; both verapamil and diltiazem are Non-<abbr title='Dihydropyridine'>DHP</abbr> <abbr title='Calcium Channel Blocker'>CCB</abbr>s, so they&#8217;d slow conduction through the AV node.</li>

<li><em>Diltiazem</em></li>

<li><em>Amiodarone</em> &#8594; useful for just about everything arrythmic, can&#8217;t go wrong there!</li>

<li><em>Metoprolol</em> &#8594; slows conduction through the AV node.</li>

<li><em>Digoxin</em> &#8594; digoxin&#8217;s only antiarrythmic role.</li>

<li>Adenosine &#8594; technically it would&#8230; for 5 seconds. Would be useful in halting a re-entry arrythmia, but not a chronic one.</li>
</ol>
</blockquote>

<blockquote>
<h3 id='question_2'><strong>Question 2</strong></h3>

<p>A patient presents with a BP of 70 and the following ECG. What would the ideal therapy be?</p>
<img src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/4vrgk46l.png' /></blockquote>

<ul>
<li>
<p><strong>Tachycardia</strong> &#8594; &#62; 100 bpm.</p>
</li>

<li>
<p><strong>Wide QRS</strong> &#8594; &#62; 120ms (3 small boxes).</p>
</li>

<li>
<p>So this is a <em>wide complex tachycardia</em>.</p>

<ul>
<li>This could either be <em>supraventricular</em> or <em>ventricular</em>.</li>

<li>A good clinical rule of thumb is to always assume it&#8217;s a <em>ventricular tachycardia</em>, because they&#8217;re the more dangerous ones!</li>
</ul>
</li>

<li>
<p>Since the patient is <em>hypotensive</em> and we&#8217;re treating it like it&#8217;s a <em>ventricular tachycardia</em>, the patient isn&#8217;t stable!</p>

<ul>
<li>We&#8217;d use <strong>shock therapy</strong>!</li>
</ul>
</li>

<li>
<p>Recall, we had that:</p>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<p>A general rule of thumb is:</p>

<ul>
<li>If the patient is <em>stable</em> &#8594; antiarrythmics are okay.</li>

<li>If the patient is <em>unstable</em> &#8594; electrical interventions like defibrillators should be used.</li>

<li>If the patient is <em>dead</em> &#8594; CPR, electricity, drugs, use everything!</li>
</ul>
</blockquote>                
                </div>
            </div>
            <div class="pagination">
                <div style="width:50%; float:left;">
                     
                        <a class="newer" href="http://www.schulichnotes.com/cardiology/2014/02/12/mechanism-arrythmia.html"><i class="fa fa-angle-left"></i> Mechanism of Arrythmia</a> 
                     
                </div>
                <div style="width:50%; float:right;">
                     
                        <a class="older" href="http://www.schulichnotes.com/cardiology/2014/02/13/atrial-fibrillation.html">Atrial Fibrillation <i class="fa fa-angle-right"></i></a> 
                     
                </div>
            </div>
        </div>
    </div>
    <script src="http://www.schulichnotes.com/cardiology/index.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/search.css">	
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch_set.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/classie.js" type="text/javascript"></script>
<script>
var search = document.getElementById('header-search-icon');
var searchbar = document.getElementById('header-search-bar');
search.onclick = function(){classie.toggle(searchbar, 'search-bar-open');}
$(document).ready(function() {$('#tipue_search_input').tipuesearch();});
</script>
</body>
</html>